Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
Bryce C. Simes, Gordon G. MacGregor
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 2125-2136
Open Access | Times Cited: 70

Showing 51-75 of 70 citing articles:

In-Home Management of Diabetes and Obesity
Sonya L. Kowalski, S Gifford
Home Healthcare Now (2024) Vol. 42, Iss. 1, pp. 6-12
Closed Access
Contrast-induced acute kidney injury; possible ameliorative effect of sodium-glucose co-transporter 2 inhibitors
Hamid Nasri
Journal of Renal Endocrinology (2024) Vol. 10, pp. e25142-e25142
Open Access
Type 2 diabetes mellitus: Novel targets and multitarget-directed phytotherapy
Abu Sufiyan Chhipa, Srashti Verma, Snehal S. Patel
Elsevier eBooks (2024), pp. 385-408
Closed Access
Renal outcomes of combination therapy with sodium-glucose cotransporter 2 inhibitors plus renin-angiotensin system blockers in patients with type 2 diabetes mellitus: A population-based cohort study
Ming‐Hsien Tsai, Mingchih Chen, Yen-Chun Huang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Effectiveness and mechanisms of sodium-dependent glucose transporter 2 inhibitors in type 2 diabetes and heart failure patients
Y. Zhang, Haisheng Hu, Baoqing Sun
World Journal of Cardiology (2024) Vol. 16, Iss. 10, pp. 611-615
Closed Access
A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents
Bantayehu Addis Tegegne, Adane Adugna, Aderaw Yenet, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
SGLT-2i: Nanoparticular-Based Strategies, Solutions, and Clinical Applications in Opposition to Low Bioavailability
Burcu Üner, Osman Yeşildağ
Journal of Pharmaceutical Innovation (2023) Vol. 18, Iss. 4, pp. 2464-2470
Closed Access | Times Cited: 1
A review on diabetes mellitus: complications, synthetic anti-diabetic agents and herbal treatment
Toluwani Tella, Carolina H. Pohl, Kovalchuk Igor
F1000Research (2024) Vol. 13, pp. 124-124
Open Access
MANAGEMENT OF TYPE 2 DIABETES
Maitham Abdallah Albajy, Dan Mihăilescu
Health Problems of Civilization (2024)
Open Access
SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM
Rajesh Patel, Terry Oroszi
Pharmacology & Pharmacy (2024) Vol. 15, Iss. 12, pp. 490-507
Open Access
Random-walk model of the sodium-glucose transporter SGLT2 with stochastic steps and inhibition
Yan Borges Barreto, Adriano M. Alencar
Journal of Physics Condensed Matter (2022) Vol. 34, Iss. 18, pp. 184004-184004
Closed Access | Times Cited: 2
Conventional and Alternative Mesenchymal Stem Cell Therapies for the Treatment of Diabetes
Lubna Rifai, Fatima Saleh
Advances in experimental medicine and biology (2020), pp. 97-106
Closed Access | Times Cited: 2
Penghambat Sodium-Glucose Cotransporter-2
David Christianto Yohanes
Acta Pharmaciae Indonesia Acta Pharm Indo (2020) Vol. 8, Iss. 1, pp. 26-26
Open Access | Times Cited: 1
Infectious complications of newer agents in the fight against diabetes
Kayla R. Stover, Emily Hugh, Justin J. Sherman, et al.
The Nurse Practitioner (2020) Vol. 45, Iss. 11, pp. 17-24
Closed Access | Times Cited: 1
Interaction between the gut microbiota and oral antihyperglycemic drugs
U. V. Buyvalenko, E. V. Pokrovskaya
Problems of Endocrinology (2022) Vol. 68, Iss. 2, pp. 66-71
Open Access | Times Cited: 1
Dapagliflozin-induced long-term and severe anorexia and weight loss: An extraordinary case
Erkan Cüre, Hakan Şirin, Medine Cumhur Cüre, et al.
Indian Journal of Pharmacology (2021) Vol. 53, Iss. 2, pp. 174-174
Open Access | Times Cited: 1
Sodium-Glucose Cotransporter 2 Inhibitors
George Dailey, Joel Rodríguez‐Saldaña
Springer eBooks (2023), pp. 581-592
Closed Access
Neoplasia Peniana: Diagnóstico Mascarado por Inibidores do SGLT2
Ana João Silva, José Guilherme Pereira, Hugo Cadavez
Gazeta Médica (2023), pp. 327-330
Open Access
Nem-inzulintermészetű vércukorcsökkentők az 1-es típusú diabetes komplementer antidiabetikus kezelésében
László Schandl, Gábor Winkler
Diabetologia Hungarica (2020) Vol. 28, Iss. 5, pp. 275-280
Open Access
Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 25, pp. 2850-2863
Open Access
Effect of sodium-glucose cotransporter type 2 inhibitors on non-alcoholic fatty liver disease
Л. А. Суплотова, D. S. Kulmametova, A. I. Fedorova, et al.
Meditsinskiy sovet = Medical Council (2022), Iss. 15, pp. 83-89
Open Access
Previous Page - Page 3

Scroll to top